U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

BioMarin Also Pausing Further Enrollment of Additional Participants Outside the U.S. in Phearless Phase 1/2 Study

close

Get every new post delivered right to your inbox.

Original Source